kras-mutant
Entity, reached from Hormuz.
- Evidence
- 51 documents · 34 separate publishers
- Standing
- Added automatically from coverage
- Time
- first seen 11 Mar 2026, last seen 6 Oct 2026
- Measured
- 16% of mentions say something specific about it; the rest only name it
- As of
- 10 Oct 2026
Where this comes from
- bioRxiv Cancer Biology · 2026-10-02 · Acute Metabolic Switch by High-Dose Dehydroascorbic Acid: Rapid TCA Cycle Depletion and Early Signature of Methionine Trap within 1 Hour in KRAS-Mutant Cells (opens the source in a new tab)
- J Drug Target · 2026-09-28 · Molecular Mechanisms of Resistance to KRASG12C Inhibitors in NSCLC- From Genomic Evolution to TME Adaptation. (opens the source in a new tab)
- Eur J Med Chem · 2026-09-24 · Design, synthesis, and structural optimization of novel pan-KRAS degrader for the treatment of KRAS-mutant pancreatic cancer. (opens the source in a new tab)
- J Natl Compr Canc Netw · 2026-09-18 · Targeting KRAS-Mutant Lung Cancers. (opens the source in a new tab)
- Cancer Chemother Pharmacol · 2026-09-17 · Main pulmonary artery enlargement during bevacizumab therapy in KRAS-mutant metastatic colon cancer. (opens the source in a new tab)
- Cell Rep · 2026-09-17 · PADI-dependent mitochondrial adaptation drives resistance to KRAS inhibitors. (opens the source in a new tab)
- Med Oncol · 2026-09-10 · Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers. (opens the source in a new tab)
- crc-digest · 2026-08-29 · Olive Oil Compound Oleocanthal Shows Promise Against KRAS-Mutant CRC (opens the source in a new tab)
What is claimed about it
Situations it is named in
Who it moves with
- co-mentioned with kras (51 documents)seen together
- co-mentioned with colorectal cancer (20 documents)seen together
- co-mentioned with lung cancer (9 documents)seen together